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INTRODUCTION
The present-day understanding of the role of vitamin D in the 
human body goes far beyond its primary function as regulator 
of calcium and phosphate metabolism. The role played by 
vitamin D in normal energy metabolism in the body, in the 
functioning of the immune system and cardiovascular system 
is receiving increasing attention. A relationship between vi-
tamin D deficiency in the serum and the occurrence of risk 
factors of cardiovascular diseases, such as hypertension [1], 
hyperlipidaemia [2], diabetes [3] and known cardiovascular 
events, including coronary heart disease, stroke and myocar-
dial infarction [4] has been demonstrated.
The described effects result from a regulation of gene 
transcription by a vitamin D active metabolite, namely 
1a,25-dihydroxyvitamin D3 [1,25(OH)2D3], which acts 
through the vitamin D nuclear receptor [5]. The VDR activated 
by 1,25(OH)2D3 interacts with the promotor region of target 
genes after the formation of a transcription complex with 
ligands. Vitamin D receptor (VDR) acting as a transcription 
factor has an influence on hormonal secretion, immunological 
response, cell division and differentiation [6].
The present paper considers studies of the effect of 
respective VDR polymorphisms on the risk of cardiovascular 
events. Propositions trying to elucidate observations are also 
presented. 
VDR
VDR belongs to a nuclear receptor family that consists, for ex-
ample, of steroid-dependent receptors and retinoic acid recep-
tors. VDR forms homodimers or heterodimers with one of the 
retinoid X receptors (RXRa, RXRb, RXRg) according to the cell 
type and finally interacts with its DNA binding site (VDRE) [7]. 
An activated VDR as a transcription factor has an effect on 
the activity of genes associated with innate immunity of the body 
(increases synthesis of antimicrobial peptides and cytokines) 
(Table 1) [8]. VDR possesses immunomodulating properties. An 
inhibition of genes encoding interleukin 17 and 17A protein and 
CCR-6 chemokine receptor [9] by VDR has been demonstrated. 
Furthermore, an inhibition in vitro of neoplastic cell proliferation 
(breast cancer, prostate cancer, colonic carcinoma) by activated 
VDR was observed. This effect is probably connected with an 
increase in synthesis of inhibitors of cyclin-dependent kinases, 
such as p21, p27, with concurrent inhibition of synthesis of 
transcription factors c-myc and c-fos. An induction of apoptosis 
in neoplastic cells through inhibition of synthesis of Bcl-2 by 
VDR has been also demonstrated [10].
Table 1. Influence of vitamin D receptor on selected signalling molecules
Effect Influence on signalling molecules
Immunomodulating effect ≠AMPs, cathelicidins, IL-4
ØINF-g, TNF-a, MMP-9, IL-17, IL-17A, IL-1b, MCP-1, ICAM-1, VCAM-1, CCR6
Regulation of calcium and phosphate metabolism ≠CaBP, osteocalcin, osteoponin
Øcollagen
Anti-proliferative effect ≠p21, p27
ØBcl-2, c-fos, c-myc
≠amplification, Øinhibition; AMPs —antimicrobial proteins; IL — interleukin; INF-g — interferon-g; TNF-a — tumour necrosis factor-a; MMP-9 — 
matrix metalloproteinase-9; MCP-1 — monocyte chemotactic protein-1; ICAM — intercellular adhesion molecule; VCAM — vascular cell adhesion 
molecule; CCR — C-C chemokine receptor; CaBP — calcium-binding protein; p21, p27 — cyclin-dependent kinase inhibitors; Bcl-2 — antionco-
gen; c-fos, c-myc — protooncogenes
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VDR GENE
More than 470 VDR single nucleotide polymorphisms 
(SNPs) have been determined so far. The VDR encoding 
gene is located on chromosome 12 and contains nine exons 
[11]. The greater part of the studies describing VDR SNP 
have concerned five SNPs in the Caucasian population: 
rs10735810 – Foc1 in exon 2, rs1544410 – BsmI in intron 
8, rs731236 – Taq1 in exon 9, rs7975232 – Apa1 in intron 
8, and rs757343 – Tru91 in intron 8. The significance of the 
respective SNPs results from their different locations in the 
VDR encoding gene. The Focl polymorphism is located at 
the site encoding a DNA-binding domain sequence of VDR 
protein. The other SNPs are located in DNA sequences en-
coding ligand domains [12].
Special attention has been paid to the BsmI and Focl poly-
morphism. The presence of BsmI SNP leads to an alternative 
VDR mRNA splicing in vitro [13]. The VDR Focl gene single 
nucleotide polymorphism determines two potential VDR 
gene transcription start points, which results in the synthesis 
of two alternative versions of the VDR protein: a long and 
a short one. A greater regulatory ability of the VDR protein 
short version has been observed [14]. 
VDR POLYMORPHISM AND RISK  
OF CORONARY HEART DISEASE
The risk of coronary heart disease (CHD) according to VDR 
polymorphism has been the subject of cohort studies that 
have covered populations differing in quantity and ethnicity.
In the study carried out by van Shooten et al. [15] that 
covered 41 Caucasian patients with documented CHD, 
a result close to statistical significance indicating a higher 
incidence of CHD in carriers of bb allele pair of BsmI VDR 
(OR 4.2; 95% CI 0.8–22.5; p = 0.06) was obtained. Unlike 
van Shooten et al. [15], Ortlepp et al. [16] demonstrated an 
increased risk for CHD among carriers of BB allele pair of BsmI 
VDR. This study was carried out in 293 Caucasian patients 
(OR 1.32; 95% CI 1.1–1.58; p = 0.05) [15].
Moreover, two successive studies performed by Shanker 
et al. [17] (287 patients of Indian origin) and Pan et al. [18] 
(152 patients of Chinese origin) have not shown a relationship 
between VDR BsmI and Focl single nucleotide polymorphism 
and increased risk of CHD. An increased risk of CHD in car-
riers of VDR BsmI single nucleotide polymorphism has also 
not been confirmed in the study carried out by Ortlepp et al. 
(3,441 Caucasian patients) [16]. 
VDR POLYMORPHISM  
AND ARTERIAL HYPERTENSION
The VDR BsmI and Focl gene polymorphism was the only one 
shown to be associated with a risk of arterial hypertension. 
Muray et al. [19] carried out genotyping in 590 healthy per-
sons (260 men, 330 women). A higher systolic blood pressure 
was found in men who were carriers of VDR BsmI gene bb 
homozygote compared to other genotypes (p < 0.006) [19]. 
Unlike Muray et al. [19], Lee et al. [20] demonstrated among 
798 healthy persons of Korean origin a statistically significant 
higher systolic (by 2.7–3.7 mm Hg) and diastolic pressure 
(by 1.9–2.5 mm Hg) in carriers of B allele of VDR BsmI gene. 
Arterial hypertension was found more frequently in this group 
than in persons with a different VDR polymorphism (OR 2.1; 
95% CI 1.0–4.4; p = 0.05) [20].
Wang et al. [21] have also shown among 695 men an 
increased risk of arterial hypertension in carriers of VDR BsmI 
gene bb homozygote and VDR Focl gene ff homozygote (OR 
1.25; 95% CI 1.04–1.51; p > 0.05; and OR = 1.32; 95% CI 
1.03–1.70; p > 0.05; respectively) [21].
VDR POLYMORPHISM  
AND OTHER CARDIOVASCULAR EVENTS
El-Shehaby et al. [22] carried out genotyping of VDR BsmI 
single nucleotide polymorphism in 80 patients with chronic 
renal failure. It was shown that left ventricular hypertrophy 
— a risk factor which is a prognostic indicator of chronic 
renal failure — is found statistically significantly more often 
in carriers of B-allele of VDR BsmI gene single nucleotide 
polymorphism than in carriers of different genotypes (b-allele 
of VDR BsmI, other SNPs) [22]. 
At the same time, Ortlepp et al. [23] demonstrated an 
increased risk of myocardial infarction in carriers of B-allele of 
BsmI VDR (OR 1.38; 95% CI 1.07–1.79; p = 0.016). How-
ever, the authors emphasised that the behavioural (tobacco 
smoking, alcohol consumption) risk of myocardial infarction 
is, after all, of greater importance than that of genetic risk 
factors including BsmI polymorphism.
These observational studies were an attempt to iden-
tify the role of the VDR polymorphism in cardiovascular 
events. 1,25(OH)2D3 acting through VDR regulates the 
transcription of genes responsible for several key reactions in 
the body. A proposition based on in vitro studies and clinical 
observations that the protective effect of vitamin D on the 
cardiovascular system is manifested by regulation of inflamma-
tory reaction, which is of key importance in the atheromatous 
plaque formation (Table 2), was submitted. Furthermore, 
vitamin D has an antiproliferative effect on monocytes in 
cardiac-muscle hypertrophy and regulating action on the 
renin–angiotensin system.
A relationship between specific VDR polymorphism and 
risk of cardiovascular events was not unequivocally indicated 
by the studies presented above. However, further research 
should undoubtedly look into whether VDR mediates the 
biological activities of cardioprotective vitamin D in order to 
elucidate this mechanism of action.
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